A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma

被引:49
|
作者
Donnenfeld, Eric D. [1 ]
Solomon, Kerry D. [2 ]
Voskanyan, Lilit [3 ]
Chang, David F. [4 ]
Samuelson, Thomas W. [5 ]
Ahmed, Iqbal Ike K. [6 ]
Katz, L. Jay [7 ]
机构
[1] Ophthalm Consultants Long Isl, Ryan Med Arts Bldg,2000 North Village Ave, Rockville Ctr, NY 11570 USA
[2] Carolina Eyecare Phys, Mt Pleasant, SC USA
[3] SV Malayan Ophthalmol Ctr, Yerevan, Armenia
[4] Altos Eye Phys, Los Altos, CA USA
[5] Minnesota Eye Consultants, Minneapolis, MN USA
[6] Univ Toronto, Toronto, ON, Canada
[7] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Philadelphia, PA 19107 USA
来源
CLINICAL OPHTHALMOLOGY | 2015年 / 9卷
关键词
iStent; MIGS; OAG; intraocular pressure; IOP reduction;
D O I
10.2147/OPTH.S91732
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate 3-year safety and intraocular pressure (IOP) following two trabecular microbypass stents in phakic and pseudophakic subjects with open-angle glaucoma (OAG) not controlled on preoperative medication. Patients and methods: In this prospective pilot study, phakic or pseudophakic subjects with OAG and IOP between 18 mmHg and 30 mmHg on one preoperative topical ocular hypotensive medication underwent medication washout. Thirty-nine qualified subjects with preoperative unmedicated IOP >= 22 mmHg and <= 38 mmHg received two stents. Postoperative examinations were scheduled at Day 1, Week 1, Months 1, 3, 6, and 12, and semiannually through Month 60. Ocular hypotensive medication was considered if postoperative IOP exceeded 21 mmHg. IOP, medication use, and safety were assessed at each visit. Subject follow-up through Month 36 was completed. Results: Thirty-six eyes (92.3%; 95% confidence interval [ CI] 79.1%, 98.4%) achieved the primary efficacy end point of Month 12 reduction in IOP >= 20% from baseline (unmedicated IOP) without ocular hypotensive medication. Four subjects required medication during the Month 36 follow-up period. Mean IOP at 36 months for subjects not taking medication was 15.2 mmHg. At 36 months, subjects sustained mean IOP decrease of 9.1 +/- 2.7 mmHg (95% CI 8.0 mmHg, 10.14 mmHg), or 37% IOP reduction, from unmedicated baseline IOP. Compared to preoperative medicated IOP, subjects had mean reduction at Month 36 of 5.5 +/- 2.7 mmHg (95% CI 4.5 mmHg, 6.6 mmHg), or 26% reduction. Both measures of IOP reduction were highly significant (P<0.001). Other than one case of early postoperative hyphema that resolved at 1 week, no postoperative adverse events were attributed to stent implantation. Conclusion: In a pilot study, two trabecular microbypass stents to treat OAG subjects on one preoperative medication provided statistically significant, sustained, and safe reduction of IOP to <= 15 mmHg without medication through 36 months.
引用
收藏
页码:2057 / 2065
页数:9
相关论文
共 50 条
  • [41] Enlargement of parapapillary atrophy in follow-up of chronic open-angle glaucoma
    Budde, WM
    Jonas, JB
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (04) : 646 - 654
  • [42] Ultrasound Cyclo Plasty for Treatment of Surgery-Naive Open-Angle Glaucoma Patients: A Prospective, Multicenter, 2-Year Follow-Up Trial
    Figus, Michele
    Posarelli, Chiara
    Nardi, Marco
    Stalmans, Ingeborg
    Vandewalle, Evelien
    Melamed, Shlomo
    Skaat, Alon
    Leshno, Ari
    Sousa, David Cordeiro
    Pinto, Luis Abegao
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [43] Five-Year Outcomes Prospective Study of Two First-Generation Trabecular Micro-Bypass Stents (iStent®) in Open-Angle Glaucoma
    Saheb, Hady
    Donnenfeld, Eric D.
    Solomon, Kerry D.
    Voskanyan, Lilit
    Chang, David F.
    Samuelson, Thomas W.
    Ahmed, Iqbal Ike K.
    Katz, L. Jay
    CURRENT EYE RESEARCH, 2021, 46 (02) : 224 - 231
  • [44] Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication
    Katz, L. Jay
    Erb, Carl
    Carceller Guillamet, Amadeu
    Fea, Antonio M.
    Voskanyan, Lilit
    Wells, Jeffrey M.
    Giamporcaro, Jane Ellen
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 2313 - 2320
  • [45] The Ibopamine provocative test in patients with diagnosis of open-angle glaucoma: a ten-year follow-up
    Giraldi, JP
    Santerelli, S
    Di Tizio, F
    Saguto, D
    Cordiani, B
    Zaccara, F
    Paone, E
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1999, 77 : 61 - 62
  • [46] A retrospective study on the effects of laser trabeculoplasty in open-angle glaucoma: a 10-year follow-up
    Arrico, L
    Taverniti, L
    Donati, S
    Recupero, SM
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 : 57 - 58
  • [47] 12-month outcomes of trabecular microbypass iStent inject W implantation combined with cataract surgery in open-angle glaucoma eyes
    El Bakkali, Ismael Bakkali
    Arias, Pablo Cisneros
    Rivases, Guillermo Perez
    Moscarda, Eva Josefina Nunez
    De Rivas, Marta Orejudo
    Fernandez, Miguel Castillo
    Claveria, Julia Aramburu
    Martinez, Marta Suner
    Garcia, Diana Perez
    Ascaso, Javier
    Ibanez, Juan
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [48] 10 YEAR PROSPECTIVE FOLLOW-UP OF A GLAUCOMA OPERATION - THE DOUBLE FLAP SCHEIE IN PRIMARY OPEN ANGLE GLAUCOMA
    GREVE, EL
    DAKE, CL
    KLAVER, JHJ
    MUTSAERTS, EMG
    INTERNATIONAL OPHTHALMOLOGY, 1985, 8 (03) : 139 - 146
  • [49] A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma
    Ahmed, Iqbal Ike K.
    Podbielski, Dominik W.
    Patel, Vardhaman
    Falvey, Heather
    Murray, Judith
    Botteman, Marc
    Goeree, Ron
    OPHTHALMOLOGY GLAUCOMA, 2020, 3 (02): : 103 - 113
  • [50] Open-angle glaucoma and mortality: A long-term follow-up study
    Sundqvist, Julius
    Ekstrom, Curt
    ACTA OPHTHALMOLOGICA, 2018, 96 (08) : E1038 - E1039